205 results on '"Wedner, H James"'
Search Results
2. mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes
3. Optimization of care for patients with hereditary angioedema living in rural areas
4. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
5. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
6. Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey
7. Efficacy And Safety Of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant In Prophylaxis Of Hereditary Angioedema Attacks: Results Of CHAPTER-1 Phase 2 Trial
8. Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks
9. Using N-Glycosylation as a Tool to Study C1 Esterase Inhibitor Expression and Function
10. Long-Term Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema From the United States and Canada: Final Data From the EMPOWER Study
11. Immunoglobulin replacement products confer in vivo protection against SARS-CoV-2 XBB.1.5 Omicron variant despite poor neutralizing activity
12. Penicillin Allergy Evaluation: A Prospective, Multicenter, Open-Label Evaluation of a Comprehensive Penicillin Skin Test Kit
13. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety (TATE study).
14. Effectiveness, Safety, and Patient-Reported Outcomes (PROs) in Patients With Hereditary Angioedema (HAE) From the United States and Canada Treated With Lanadelumab: 24-Month Data From the EMPOWER Study
15. Understanding the Mechanism of the Disproportionately Reduced C1-Esterase Inhibitor (C1-INH) Levels in Hereditary Angioedema (HAE)
16. Efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years old with hereditary angioedema (HAE) in the phase 3, open-label, multicenter SPRING Study
17. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients
18. Insights into the pathogenesis of hereditary angioedema using genetic sequencing and recombinant protein expression analyses
19. Factors that predict the success of cyclosporine treatment for chronic urticaria
20. Impact of lanadelumab on patient-reported outcomes in hereditary angioedema in the US and Canada: Interim findings from the EMPOWER Study
21. Sustained Reductions in Hereditary Angioedema (HAE) Attack Rates Observed over 96 Weeks of Oral Berotralstat Treatment Regardless of Initial Response
22. Patients With Primary Antibody Deficiency Syndromes Show Attenuated Neutralizing Activity of SARS-CoV-2 Following COVID-19 Vaccination
23. mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in patients with antibody deficiency syndromes
24. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
25. Relationship of Biosynthesis of Slow Reacting Substance to Intracellular Glutathione Concentrations
26. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
27. Randomized trial of the efficacy and safety of Berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 ihrough 48 weeks (Part 2)
28. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
29. Elective penicillin skin testing in a pediatric outpatient setting
30. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH)
31. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)
32. Relative Reductions in Attack Rate With Prophylactic Berotralstat (BCX7353) in Subjects with Hereditary Angioedema (HAE): Responder Analysis from the APeX-2 Study
33. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study
34. Eosinophilia in an Iranian woman
35. Aeropollen of herbaceous plants at Corpus Christi, Texas
36. A randomized clinical trial to reduce asthma morbidity among inner-city children: Results of the National Cooperative Inner-City Asthma Study
37. Immune globulin subcutaneous, human – klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study
38. Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
39. A Questionnaire Survey Study To Determine Association of Dental Hygiene Practices in Hereditary Angioedema Subjects with The Incidence of Post-Procedural Angioedema Attacks
40. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial : the OPuS‐2 study
41. Long term efficacy of Omalizumab for patients with refractory chronic urticaria and angioedema
42. Clinical trials report
43. Chronic Fatigue Syndrome: Point and Counterpoint
44. Allergic Reactivity to Parthenium Hysterophorus Pollen: An Unrecognized Type I Allergen
45. Something new in the air: Paying for community-based environmental approaches to asthma prevention and control
46. Selective Response to Rituximab in a Patient with Salivary Gland-Predominant IgG4-Related Disease.
47. Neuropsychiatric Associations with Drug Allergy
48. Pharmacodynamic Effect of DX-2930 on Plasma Kallikrein in Hereditary Angioedema Patients
49. Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema
50. Refined Method for Collection of Plasma Samples to Evaluate the Role of Plasma Kallikrein in Various Disease States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.